latamoxef 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, oxacefalosporanic acid derivatives 1851 64952-97-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • latamoxef disodium
  • latamoxef
  • moxalactam
  • lamoxactam
  • moxam
  • latamoxef sodium
  • moxalactam disodium
  • moxalactam disodium salt
Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
  • Molecular weight: 520.47
  • Formula: C20H20N6O9S
  • CLOGP: -0.47
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 4
  • TPSA: 206.30
  • ALOGS: -2.84
  • ROTB: 9
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 76 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 54.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.72 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.464 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.805 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.232 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.560 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 47.180 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 38.690 % High 1
herg hERG pIC50 4.682 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.361 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.776 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 23.070 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1 36
kinase-selectivity-class AXL,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC,STK33,TEK 10
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.413 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.832 High 1
mppb Mouse plasma protein binding (% unbound) 62.830 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.211 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 37.760 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.432 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.240 % High 1
rppb Rat plasma protein binding (% unbound) 22.950 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 872.971 uM High 1

Approvals:

DateAgencyCompanyOrphan
None FDA LILLY

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefotaximecefpiramidecefpodoxime proxetilcefsulodin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.92 acidic
pKa2 7.41 acidic
pKa3 9.82 acidic
pKa4 13.92 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 5.94 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.72 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 4.64 WOMBAT-PK CHEMBL

External reference:

IDSource
4017540 VUID
N0000179709 NUI
D02198 KEGG_DRUG
4017540 VANDF
4019847 VANDF
C0026651 UMLSCUI
CHEBI:599928 CHEBI
MXL PDB_CHEM_ID
CHEMBL74632 ChEMBL_ID
CHEMBL1200357 ChEMBL_ID
DB04570 DRUGBANK_ID
12031 IUPHAR_LIGAND_ID
64953-12-4 SECONDARY_CAS_RN
47499 PUBCHEM_CID
258330 RXNORM
002806 NDDF
004889 NDDF
350135006 SNOMEDCT_US
387099009 SNOMEDCT_US
387259002 SNOMEDCT_US
D009070 MESH_DESCRIPTOR_UI
4880 INN_ID
VUF6C936Z3 UNII

Pharmaceutical products:

None